ALPHA-BSM, BETA-BSM, GAMMA-BSM, EQUIVABONE

K091607 · Etex Corp. · MQV · Nov 2, 2009 · Orthopedic

Device Facts

Record IDK091607
Device NameALPHA-BSM, BETA-BSM, GAMMA-BSM, EQUIVABONE
ApplicantEtex Corp.
Product CodeMQV · Orthopedic
Decision DateNov 2, 2009
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3045
Device ClassClass 2
AttributesTherapeutic

Intended Use

Gamma-bsm Moldable Bone Substitute Material is an implantable bone graft that is a synthetic calcium phosphate, poorly crystalline hydroxyapatite material intended for use in filling bone voids or defects of the skeletal system (i.e. the extremities, posterolateral spine and pelvis) that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. Gamma-bsm Moldable Bone Substitute Material is a bone graft substitute that resorbs and is replaced with new bone during the healing process.

Device Story

Synthetic, biocompatible bone graft substitute; composed of powder component mixed with solution to form putty. Applied manually to skeletal bone voids/defects; shaped in-situ. Hardens at body temperature; converts to poorly crystalline hydroxylapatite (PCHA). Osteoconductive; resorbs and replaced by natural bone during healing. Used by surgeons in clinical settings for non-structural bone defects.

Clinical Evidence

Bench testing only; regression testing performed in accordance with Class II Special Controls Guidance Document: Resorbable Calcium Salt Bone Void Filler Device.

Technological Characteristics

Synthetic calcium phosphate; poorly crystalline hydroxyapatite. Material is a powder/solution mix that hardens in-situ. Osteoconductive. No electronic components or software.

Indications for Use

Indicated for filling non-structural osseous defects of the skeletal system, including extremities, posterolateral spine, and pelvis, in patients with surgically created or traumatic bone voids.

Regulatory Classification

Identification

A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K091607 Traditional 510(k) Submission -Bone Void Fillers #### 510(k) Summary - Gamma-bsm 5.3 | Submitter: | ETEX Corporation<br>38 Sidney Street<br>Cambridge, MA 02139<br>Registration No.: 1225112<br>Owner/Operator No.: 9014709 | NOV - 2 2005 | |------------|-------------------------------------------------------------------------------------------------------------------------|--------------| |------------|-------------------------------------------------------------------------------------------------------------------------|--------------| Contact Person: Christopher Klaczyk Regulatory Affairs Manager Office: (617) 577-7270 x160 Mobile: (617) 710-8091 Fax: (617) 577-7170 E-Mail: cklaczyk@etexcorp.com Date Prepared: August 3, 2009 Product Code(s): MQV (21 CFR 888.3045) Device Class: II (21 CFR 888.3045) Classification Panel: Orthopaedics FDA Panel Number: 87 Classification Name: Filler, Bone Void, Calcium Compound (21 CFR 888.3045) Proprietary Name: Gamma-bsm Moldable Bone Substitute Material Predicate Device(s): Gamma-bsm Moldable Bone Substitute Material (ETEX Corporation, K090242) Vitoss Bioactive Foam Bone Graft Substitute (Orthovita, K083033) Device Description: Gamma-bsm Moldable Bone Substitute Material is a synthetic, biocompatible bone graft substitute material. At the time of use, the powder component is combined with a specified volume of mixing solution and mixed to form a putty. The resulting putty is administered to the treatment site by manual application. The material can be shaped into a desired form in-situ prior to implantation. After the putty is applied to the treatment site, it hardens at body temperature and converts to an apatitic calcium phosphate material. The end product, poorly crystalline hydroxylapatite (PCHA), is of low crystalline order with a similar chemical and crystalline structure to that of natural bone {1}------------------------------------------------ Traditional 510(k) Submission -Bone Void Fillers minerals. Gamma-bsm Moldable Bone Substitute Material is an osteoconductive material that is resorbed and replaced by natural bone over time. ### Intended Use: Gamma-bsm Moldable Bone Substitute Material is an implantable bone graft that is a synthetic calcium phosphate, poorly crystalline hydroxyapatite material intended for use in filling bone voids or defects of the skeletal system (i.e. the extremities, posterolateral spine and pelvis) that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. Gamma-bsm Moldable Bone Substitute Material is a bone graft substitute that resorbs and is replaced with new bone during the healing process. #### Materials: **Performance Data** Performance Data: Regression testing consistent with Class II Special Controls Guidance Document: Resorhable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA Staff (dated June 2, 2003) has been submitted. Synthetic calcium phosphate ## ETEX Corporation Page 5-6 pg 2 of 2 {2}------------------------------------------------ # DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the seal of the Department of Health and Human Services (HHS) of the United States. The seal features the department's name in a circular arrangement around the perimeter, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" clearly visible. In the center of the seal is a stylized representation of a bird-like figure, which is a common symbol associated with HHS. #### Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-066-0609 Silver Spring, MD 20993-0002 ETEX Corporation % Mr. Christopher Klaczyk Regulatory Affairs Manager 38 Sidney Street, 3flr, The Clark Building Cambridge, MA 02139 NOV - 2 2009 Re: K091607 Trade/Device Name: Gamma-bsm Moldable Bone Substitute Material Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone voice filler device Regulatory Class: II Product Code: MOV Dated: September 11, 2009 Received: September 14, 2009 Dear Mr. Klaczyk: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ Page 2 - Mr. Christopher Klaczyk If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours, Sincerely yours, Mark N. Melkerson Director Director Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ #### Indications For Use - Gamma-bsm 4.3 K091607 510(k) Number (if known): Gamma-bsm Moldable Bone Substitute Material Device Name: Indications for Use: Gamma-bsm Moldable Bone Substitute Material is an implantable bone graft that is a synthetic calcium phosphate, poorly crystalline hydroxyapatite material intended for use in filling bone voids or defects of the skeletal system (i.e. the extremities, posterolateral spine and pelvis) that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. Gamma-bsm Moldable Bone Substitute Material is a bone graff substitute that resorbs and is replaced with new bone during the healing process. Prescription Use _____________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) FOR M.MELKERSON Division Sign-Off (Dision Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number K09166 ETEX Corporation
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%